Cochlear Implants Clinical Trial
— ENPICMEOfficial title:
Estimation of Perceptual Levels Used in Cochlear Implant Fitting Based on Electrophysiological Measures
Verified date | September 2021 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this research is to evaluate the relationships between multiple data from cochlear implant (CI) adult users to and to estimate predictive models of their fitting parameters. In a group of patients, the Electrically-evoked Compound Action Potentials (ECAP) will be collected intra-operatively and the correlation with demographic data (deafness duration, age deafness onset, etiology, duration of cochlear implant use of CI), auditory performances and subjective measures used for implant fitting (hearing threshold and most comfortable level) will be calculated. In a second group of experienced users (more than 9months of use of their CI), ECAP and Electrically-evoked Auditory Brainstem Response (EABR) will be collected after 9 months of CI experience and after 12 months or more of use. Correlation analyzes with demographic data, performance and fitting parameters will be performed as well. Statistical predictive models for both fitting at the activation or in experienced users should be developed according to the correlation analysis. The secondary objective is to evaluate the effects of simultaneous stimulation on hearing performances. Simultaneous stimulations will be delivered in one ear (bimodal condition) in patients using an Electro-Acoustic Stimulation device (EAS) or in the two ears (binaural condition) for bilateral CI users. ECAP, EABR and speech perception will be measured and compared in the different conditions.
Status | Completed |
Enrollment | 49 |
Est. completion date | June 4, 2020 |
Est. primary completion date | June 4, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Good general health status including no neuropsychological diseases affecting intellectual capacities - Users of cochlear implant or electro-acoustic stimulation devices - Normal otoscopy - No excessive sound exposure within 48h before the measure Exclusion Criteria: - For women, possibility of pregnancy (absence of effective contraception or confirmed menopause); - Concomitant use of ototoxic or psychotropic treatment with anxiolytic and / or antipsychotic |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Edouard Herriot - Service ORL Pavillon U | Lyon |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ECAP threshold | ECAP amplitude growth function (AGF) will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for more than 11 months. ECAP thresholds (in current unit) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. These records could also be compared to ECAP AGF recorded in clinical routine/during control visit before these 11 months that includes intra-operative records when available.
The ECAP threshold recorded with and without acoustic stimulations will be compared in patients using EAS devices. |
from 11 months after cochlear implant activation | |
Secondary | ECAP threshold | ECAP AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for 9 months. ECAP thresholds (in current unit) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. | 9 months after cochlear implant activation | |
Secondary | ECAP maximal amplitude | ECAP AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for more than 11 months. ECAP maximal amplitudes (in µV) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. These records could also be compared to ECAP AGF recorded in clinical routine/during control visit before these 11 months that includes intra-operative records when available.
The ECAP amplitude recorded with and without acoustic stimulations will be compared in patients using EAS devices. |
from 11 months after cochlear implant activation | |
Secondary | ECAP maximal amplitude | ECAP AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for 9 months. ECAP maximal amplitudes (in µV) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. | 9 months after cochlear implant activation | |
Secondary | ECAP latency | ECAP AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for more than 11 months. ECAP latencies (in µs) of the ECAP recorded with the highest stimulation level will be determine , compared according to the stimulation sites and correlation tests with the other measures will be performed. These records could also be compared to ECAP AGF recorded in clinical routine/during control visit before these 11 months that includes intra-operative records when available.
The ECAP latencies recorded with and without acoustic stimulations will be compared in patients using EAS devices. |
from 11 months after cochlear implant activation | |
Secondary | ECAP latency | ECAP AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for 9 months. ECAP latencies (in µs) of the ECAP recorded with the highest stimulation level will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. | 9 months after cochlear implant activation | |
Secondary | ECAP AGF slope | ECAP AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for more than 11 months. ECAP AGF slopes (µV/qu) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. These records could also be compared to ECAP AGF recorded in clinical routine/during control visit before these 11 months that includes intra-operative records when available.
The ECAP AGF slopes recorded with and without acoustic stimulations will be compared in patients using EAS devices. |
from 11 months after cochlear implant activation | |
Secondary | ECAP AGF slope | ECAP AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for 9 months. ECAP AGF slopes (µV/qu) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. | 9 months after cochlear implant activation | |
Secondary | EABR wave V maximal amplitude | EABR AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for more than 11 months. EABR wave V maximal amplitudes (µV) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. These records could also be compared to EABR AGF recorded in clinical routine/during control visit before these 11 months. | from 11 months after cochlear implant activation | |
Secondary | EABR wave V maximal amplitude | EABR AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for 9 months. EABR wave V maximal amplitudes (µV) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. | 9 months after cochlear implant activation | |
Secondary | EABR wave V latency | EABR AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for more than 11 months. EABR wave V latencies (ms) recorded with the highest stimulation level will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. These records could also be compared to EABR AGF recorded in clinical routine/during control visit before these 11 months. | from 11 months after cochlear implant activation | |
Secondary | EABR wave V latency | EABR AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for 9 months. EABR wave V latencies (ms) recorded with the highest stimulation level will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. | 9 months after cochlear implant activation | |
Secondary | EABR wave V threshold | EABR AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for more than 11 months. EABR wave V thresholds (current unit) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. These records could also be compared to EABR AGF recorded in clinical routine/during control visit before these 11 months. | from 11 months after cochlear implant activation | |
Secondary | EABR wave V threshold | EABR AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for 9 months. EABR wave V thresholds (current unit) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. | 9 months after cochlear implant activation | |
Secondary | EABR wave V AGF slope | EABR AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for more than 11 months. EABR wave V AGF slopes (µV/qu) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. These records could also be compared to EABR AGF recorded in clinical routine/during control visit before these 11 months. | from 11 months after cochlear implant activation | |
Secondary | EABR wave V AGF slope | EABR AGF will be recorded on three cochlear sites (basal, medial, apical) in all patients using their implants for 9 months. EABR wave V AGF slopes (µV/qu) will be determined, compared according to the stimulation sites and correlation tests with the other measures will be performed. | 9 months after cochlear implant activation | |
Secondary | EABR binaural interaction component (BIC) | In bilaterally implanted patients using both of their implants for more than 11 months, EABR BIC will be recorded with a reference electrode of either the older implant or the one associated with the best hearing performances and all the electrodes of the second implant. EABR BIC amplitude (µV) will be determined, compared according to the electrode pairing and correlation tests with the other measures will be performed. | from 11 months after cochlear implant activation | |
Secondary | Most Comfort Level (MCL) | The MCL (current unit) will be evaluated for each electrode/cochlear site tested during the same recording session than the ECAP threshold evaluated after 11 months. These subjective limits will be compared according to the stimulation sites and correlated to ECAP and/or EABR characteristics. | from 11 months after cochlear implant activation | |
Secondary | Most Comfort Level (MCL) | The MCL (current unit) will be evaluated for each electrode/cochlear site tested during the same recording session than the ECAP threshold evaluated at 9 months. These subjective limits will be compared according to the stimulation sites and correlated to ECAP and/or EABR characteristics. | 9 months after implant cochlear implant activation | |
Secondary | Speech recognition score | The percentage of speech recognition will be measured at 60 decibels (dB) in open space with implant(s) well fitted during the same recording session than the ECAP threshold evaluated after 11 months. This performance level will be correlated to the ECAP and/or EABR characteristics. In the bimodal and binaural groups, performances will be compared between hearing conditions (monaural = 1 implant vs. bimodal or binaural hearing).
During these audiometry tests, the recognition score will be also measured at 40 and 50 dB and a pure tone audiometry will be performed. |
from 11 months after implant cochlear implant activation | |
Secondary | Speech recognition score | The percentage of speech recognition will be measured at 60 dB in open space with implant(s) well fitted during the same recording session than the ECAP threshold evaluated at 9 months. This performance level will be correlated to the ECAP and/or EABR characteristics.
During these audiometry tests, the recognition score will be also measured at 40 and 50 dB and a pure tone audiometry will be performed. |
9 months after implant cochlear implant activation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04571333 -
Feasibility of the Mi2000 Totally Implantable Cochlear Implant in Severely to Profoundly Deaf Adults.
|
N/A | |
Completed |
NCT01023932 -
Auditory Neuropathy and Cochlear Implants
|
N/A | |
Active, not recruiting |
NCT04506424 -
CT Guided CI Programming
|
N/A | |
Recruiting |
NCT04708717 -
Encoding Temporal Fine Structure for Cochlear Implants
|
N/A | |
Completed |
NCT03694340 -
Optimization of Cochlear Implant MAP-parameters in Children
|
N/A | |
Recruiting |
NCT04099368 -
Music Appreciation After Cochlear Implantation
|
N/A | |
Recruiting |
NCT03707691 -
Pitch Perception and Memory: Deficits and Training
|
N/A | |
Recruiting |
NCT05451628 -
Anatomy-Based Fitting in Unexperienced Cochlear Implant Users
|
N/A | |
Completed |
NCT03078920 -
Benefits of a Contralateral Routing of Signals (CROS) System in Unilateral CI-recipients
|
N/A | |
Completed |
NCT02892552 -
Cone Beam CT Versus Multislice CT in the Postoperative Assessment of Cochlear Implantation
|
N/A | |
Completed |
NCT04721327 -
Remote Care: The Future of Cochlear Implants
|
N/A | |
Recruiting |
NCT05369598 -
Audiological and Quality of Life Outcomes of Anatomy Based Fitting in Patients Implanted by Robot Assisted Cochlear Implant Surgery (RACIS)
|
N/A | |
Recruiting |
NCT05558514 -
Place-based Cochlear Implant Mapping
|
N/A | |
Completed |
NCT04918654 -
Automatic Sound Management 3.0 in a Single-unit Audio Processor
|
||
Recruiting |
NCT04207866 -
Auditory Training Via Teleconference
|
N/A | |
Not yet recruiting |
NCT06375278 -
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
|
N/A | |
Not yet recruiting |
NCT06453343 -
Clinical Trial to Compare Two Surgical Approaches to the Cochlea
|
N/A | |
Completed |
NCT03807830 -
Exploring the Use of ECochG Testing During Electrode Insertion in Cochlear Implant Surgery
|
N/A | |
Completed |
NCT06322472 -
The Relationship Between Phonological Awareness Skills And Home Environment Literacy in Cochlear Implant Users
|
N/A | |
Completed |
NCT03877211 -
Channel Interaction in Cochlear Implant and Speech Understanding in Noise
|
N/A |